Vanguard Capital Management
CRBP icon

Vanguard Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Vanguard Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.14M Buy
760,940
+26,834
+4% +$254K ﹤0.01% 2983
2026
Q1 		$6.89M Buy
+734,106
New +$6.18M ﹤0.01% 2925

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $214M AUM 88.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Capital Management's CRBP Position: Q2 2026 in Review

Vanguard Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 3.7% in Q2 2026, buying an estimated $254K and bringing the position to 760,940 shares worth $7.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2983.

Vanguard Capital Management first reported a position in CRBP in Q1 2026 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Vanguard Capital Management held 760,940 shares of Corbus Pharmaceuticals worth $7.14M as of Q2 2026.
  • Vanguard Capital Management bought 26,834 Corbus Pharmaceuticals shares in Q2 2026, an estimated $254K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2983 holding.
  • Vanguard Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.